IGC Pharma, Inc. 8-K

What Happened

• IGC Pharma, Inc. announced on January 5, 2026 that it entered into a Subscription Agreement with certain investors for a registered direct offering of 779,997 shares of common stock at $0.30 per share. The offering will generate gross proceeds of approximately $234,000, before estimated offering expenses.
• The offering is being made under the company’s effective Form S-3 shelf registration (File No. 333-276330, declared effective January 8, 2024) and a prospectus supplement dated January 5, 2026. Closing is expected on or about January 5, 2026, subject to customary conditions. Olshan Frome Wolosky LLP issued a legal opinion regarding the issuance; the Subscription Agreement and related exhibits are filed with the 8-K.

Key Details

• Shares to be issued: 779,997 common shares.
• Price per share: $0.30; gross proceeds: ~ $234,000 (pre-expenses).
• Use of proceeds: working capital and general corporate purposes, including funding clinical development programs and R&D.
• Offering registered under previously effective Form S-3; prospectus supplement filed January 5, 2026.

Why It Matters

• This transaction provides near-term cash for IGC’s operations and clinical programs, but it is a dilutive financing since new shares are being issued to outside investors.
• The size of the raise is modest, so investors should consider how this fits with the company’s overall funding needs and planned development timeline.
• Because the offering is registered (not a convertible note or private placement), the shares are issued under a public shelf and will increase the company’s outstanding share count once closed.